文献速递临床试验与 GCP

补中益气汤治疗耐药菌医院获得性肺炎:随机对照试验方案

Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-12-30

本研究为多中心随机对照试验方案,拟纳入200例耐药菌医院获得性肺炎患者,随机分为标准治疗组和标准治疗加补中益气汤组,疗程28天,旨在为补中益气汤治疗该病提供循证依据。

要点

  • 提出耐药菌医院获得性肺炎「急性气虚」中医病机理论。
  • 补中益气汤联合标准治疗,疗程28天,评价疗效。

核心结论

  • 研究旨在为补中益气汤治疗耐药菌医院获得性肺炎提供循证依据。

研究设计与样本

  • 多中心随机对照试验,5个研究中心急诊和ICU病房纳入患者。
  • 随机分为对照组(标准治疗)和试验组(标准治疗加补中益气汤)。
  • 治疗疗程为28天。

关键数值与推荐

  • 纳入标准为确诊耐药菌医院获得性肺炎且符合入组条件者。
  • 干预措施为在标准治疗基础上加用补中益气汤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug resistance in China is becoming a more and more serious issue. Infection by drug-resistant bacteria has become a major disease that seriously threatens the health of Chinese people and affects national medical finance. Therefore, it is of great scientific and clinical significance to actively carry out research on the prevention and treatment of infections by multi-drug resistant organisms (MDRO). Previous studies by the authors suggested that patients with hospital-acquired pneumonia caused by MDRO mostly showed the pathological state of "insufficient healthy Qi and internal accumulation of pathogenic Qi" and "acute deficiency syndrome" mainly characterized by Qi deficiency. Buzhong Yiqi decoction is a famous classic prescription in traditional Chinese medicine (TCM) for treating internal damage fever. This study intends to provide an evidence-based rationale for Buzhong Yiqi decoction in treating MDRO hospital-acquired pneumonia by conducting a multi-center randomized controlled clinical study. METHODS/DESIGN: This study is designed to be a multi-center randomized controlled study in which patients are assigned randomly into control (standard therapy) and trial (standard therapy plus Buzhong Yiqi decoction) groups. The patients will be selected from the emergency department and the ICU inpatient department of five study sites and will all be diagnosed with MDRO hospital-acquired pneumonia and meet the inclusion criteria. Forty patients are to be enrolled in each study site, resulting in a total of 200 patients in the study. The treatment course is 28 days. DISCUSSION: In this study: (1) the theory of "acute Qi deficiency" in MDRO hospital-acquired pneumonia is put forward for the first time, and the basic theories of TCM are further improved; (2) a multi-center randomized controlled clinical study will be performed for the first time with Buzhong Yiqi decoction, the classic prescription for reinforcing healthy Qi and eliminating pathogenic Qi, providing a reliable evidence-based rationale for the treatment of MDRO pulmonary infection with TCM; (3) the clinical application and modern disease spectrum of Buzhong Yiqi decoction is expanded, and the scientific notion of "treating different diseases with the same method" is enriched further. TRIAL REGISTRATION: China Clinical Trial Registry, ChiCTR1900022429. Registered on April 11, 2019. http://www.chictr.org.cn/listbycreater.aspx.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Deng D, Chen Z, Jia L, et al. Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial. Trials. 2019. PMID: 31888702. doi:10.1186/s13063-019-3927-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。